Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal

Pact Could Be Worth $353m

Executive Summary

Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.

You may also be interested in...



Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain

The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.

Bluebird Sickle Cell Gene Therapy Hangs In Balance

The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.” 

New CRISPR Therapeutics/Vertex Data Dangle The Hope Of Cure For SCD and TDT

With more data reported at ASH, Vertex and CRISPR Therapeutics added heft to the notion that functional cures are on the horizon for the inherited blood disorders sickle cell disease and beta-thalassemia. Attention is now turning to Bluebird’s marketing strategy after a filing delay.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel